Abstract
NNC 756 is a new benzazepine with high affinity and selectivity for D1-dopamine receptors. In a double-blind, placebo controlled, cross-over study, positron emission tomography and the radioligand [11C]SCH 23390 were used to determine central D1-do-pamine receptor occupancy after a single oral dose of 80 mg NNC 756 in three healthy men. NNC 756 induced 75, 66 and 47% occupancy of D1-dopamine receptors in the putamen of at 1.5 h after drug administration and 46, 36 and 24% after 7.5 h. There was a hyperbolic relationship between the occupancy values and the serum concentrations. The Ki value for the hyperbola was 6.4 ng/ml (±SD 1.4). The occupancy at 1.5 h is on the same level as that shown to induce effects in animal models for prediction of antipsychotic effect. Restlessness (akathisia) appeared in two subjects and nausea in one subject at time of peak drug concentration in serum. The oral dose level of 80 mg should be appropriate to investigate the potential antipsychotic effect of NNC 756.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andersen PH, Grønvald FC, Hohlweg R, Hansen LB, Guddal E, Braestrup C, Nielsen EB (1992) NNC-112, NNC-687 and NNC-756, new selective and highly potent dopamine D1 receptor antagonists. Eur J Pharmacol 219:45–52
Barnes TRE (1989) A rating scale for drug-induced akathisia. Br J Psychiatr. 154:672–676
Bergström M, Boëthius J, Eriksson L, Greitz T, Ribbe T, Widén L (1981) Head fixation device for reproducible position alignment in transmission CT and positron emission tomography. J Comput Assist Tomogr 5:136–141
Borison HL (1984) History and status of the area postrema. Fed Proc 43:2937–2940
Borison HL, Wang SC (1953) Physiology and pharmacology of vomiting. Pharmacol Rev 5:193–230
Camps M, Cortés R, Gueye B, Probst A, Palacios JM (1989) Dopamine receptors in human brain: autoradiographic distribution of D2 sites. Neuroscience 28:275–290
Chipkin RD, Iorio LC, Coffin VL, McQuade RD, Berger JG, Barnett A (1988) Pharmacological profile of SCH 39166: a dopamine D1 selective benzonaphtazepine with potential antipsychotic activity. J Pharmacol Exp Ther 247:1093–1102
Christensen JV (1992) Determination of (+)-5-(2,3-dihydrobenzofuran-7-yl)-3-methyl-8-nitro-2,3,4,5-tetrahydro-1H-3benzazepin-7-ol (NNC-0687), a novel dopamine D-1 receptor antagonist, in plasma by solid-phase extraction and high-performance liquid chromatography. J Chromatogr 577:366–370
Clark AJ (1937) General pharmacology. In: Heffter A (eds) Handbook of experimental pharmacology. Springer, Berlin
Clark D, White FJ (1987) Review: D1 dopamine receptor — the search for a function: a critical evaluation of the D1/D2 dopamine receptor classification and its functional implications. Synapse 1:347–388
Cortés R, Gueye B, Pazos A, Probst A, Palacios JM (1989) Dopamine receptors in human brain: autoradiographic distribution of D1 sites. Neuroscience 28:263–273
Daly SA, Waddington JL (1991) Two directions of dopamine D1/D2 receptor interactions in studies of behavioural regulation: a finding generic to four new, selective dopamine D1 receptor antagonists. Eur J Pharmacol 213:251–258
Farde L (1992) Selective D1- and D2-dopamine receptor blockade both induce akathisia in humans — a PET study with [11C]SCH 23390 and [11C]raclopride. Psychopharmacology 107:23–29
Farde L, Pauli S, Hall H, Eriksson L, Halldin C, Högberg T, Nilsson L, Sjögren I, Stone-Elander S (1988) Stereoselective binding of11C-raclopride binding in living human brain — a search for extrastriatal D2-dopamine receptors by PET. Psychopharmacology 94:471–478
Farde L, Wiesel F-A, Nordström A-L, Sedvall G (1989) D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology 99:S28-S31
Farde L, Wiesel F-A, Stone-Elander S, Halldin C, Nordström A-L, Hall H, Sedvall G (1990) D2 dopamine receptors in neuroleptic-naive schizophrenic patients. Arch Gen Psychiatry 47:213–219
Farde L, Nordström A-L, Wiesel F-A, Pauli S, Halldin C, Sedvall G (1992) PET analysis of central D1- and D2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine — relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538–544
Gibaldi M (ed) (1984). Biopharmaceutics and clinical pharmacokinetics, 3rd edn, Lea & Febiger, Philadelphia
Hall H, Farde L, Sedvall G (1988) Human dopamine receptor subtypes — in vitro binding analysis using3H-SCH 23390 and3H-raclopride. J. Neural Transm 73:7–21
Halldin C, Stone-Elander S, Farde L, Ehrin E, Fasth K-J, Långström B, Sedvall G (1986) Preparation of11C-labelled SCH 23390 for the in vivo study of dopamine D-1 receptors using positron emission tomography. Appl Radiat Isot 37:1039–1043
Halldin C, Foged C, Farde L, Karlsson P, Hansen K, Grønvald F, Swahn C-G, Hall H, Sedvall G (1993) [11C]NNC 687 and [11C]NNC 756, dopamine D-1 receptor ligands. Preparation, autoradiography and PET investigation in monkey. Nucl Med Biol 8:945–953
Hansen KT, Thomsen KF, Bundgaard H (1992) Glucoronidation of the dopamine D1-receptor antagonists NNC 0756 and NNC 0772 in liver microsomes. American Society for Pharmacology and Experimental Therapeutics, pp 172–177
Iorio LC, Barnett A, Leitz FH, Houser VP, Korduba CA (1983) SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems. J Pharmacol Exp Ther 226:462–468
Karlsson P, Farde L, Halldin C, Sedvall G, Foged C, Hansen KT, Skrumsager B (1993) [11C]NNC687 and [11C]NNC756 as radioligands for PET determination of central D1-dopamine receptors. Psychopharmacology 113:149–156
Lindstrom P, Brizzee K (1962) Relief of intractible vomiting from surgical lesions in the area postrema. J Neurosurgery 19:228–236
Litton JE, Holte S, Eriksson L (1990) Evaluation of the Karolinska new positron camera system; the Scanditronix PC2048-15B. IEEE Trans Nucl Sci 37:743–748
Mitchelson F (1992) Pharmacological agents affecting emesis. A review (part I). Drugs 43:295–315
Nielsen EB, Andersen PH (1992) Dopamine receptor occupancy in vivo: behavioral correlates using NNC-112, NNC-687 and NNC-756, new selective dopamine D1 receptor antagonists. Eur J Pharmacol 219:35–44
Niznik HB (ed) (1994) Dopamine receptors and transporters. Marcel Dekker, New York
Rinne JO, Hietala J, Ruotsalinen U, Sako E, Laihinen A, Någren K, Lehikoinen P, Oikonen V, Syvalahti E (1993) Decrease in human striatal dopamine D2 receptor density with age: a PET study with [11C]raclopride. J Cereb Blood Flow Metab 13:310–314
Schwartz J-C, Agid Y, Bouthenet M-L, Jav oy-Agid F, Llorens-Cortes C, Martres M-P, Pollard H, Sales N, Taquet H (1986) Neurochemical investigations into the human area postrema. In: Davis CJ, Lake-Bakaar GV, Grahame-Smith DG (eds) Nausea and vomiting: mechanisms and treatment. Springer, Berlin, pp 18–30
Seeman P, Lee T, Chau-Wong M, Wong K (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261:717–719
Setler PE, Sarau HM, Zirkle CL, Sauders HL (1978) The central effects of a novel dopamine agonist. Eur J Pharmacol 50:419–430
Sibley DR, Monsma FJJ (1992) Molecular biology of dopamine receptors. Trends Pharmacol Sci 13:61–69
Spitzer RL, Williams JBW (ed) (1987) Diagnostic and statistical manual of mental disorders. American Psychiatric Association, Washington, D.C.
Waddington JL, Daly SA, McCauley PG, O'Boyle KM (1994) Levels of functional interaction between D1-like and D2-like dopamine receptor systems. In: Niznik HB (eds) Dopamine receptors and transporters. Marcel Dekker, New York, pp 511–537
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Karlsson, P., Farde, L., Halldin, C. et al. Oral administration of NNC 756 — a placebo controlled PET study of D1-dopamine receptor occupancy and pharmacodynamics in man. Psychopharmacology 119, 1–8 (1995). https://doi.org/10.1007/BF02246046
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02246046